Adagene’s (ADAG) Buy Rating Reiterated at HC Wainwright

Posted by Brenda Bartman on Sep 17th, 2026

HC Wainwright reaffirmed their buy rating on shares of Adagene (NASDAQ:ADAG – Free Report) in a research note published on Monday morning, Marketbeat.com reports. They currently have a $7.00 price target on the stock. HC Wainwright also issued estimates for Adagene’s FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.87) EPS.

Other analysts have also recently issued reports about the stock. Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Adagene in a research note on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adagene in a report on Friday, July 17th. Finally, Chardan Capital initiated coverage on Adagene in a research note on Thursday, September 10th. They issued a “buy” rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $8.67.

View Our Latest Research Report on ADAG

Adagene Price Performance

NASDAQ:ADAG opened at $3.17 on Monday. The company has a quick ratio of 3.07, a current ratio of 5.02 and a debt-to-equity ratio of 0.01. Adagene has a 52 week low of $1.30 and a 52 week high of $4.85. The company has a 50-day moving average of $3.69 and a 200-day moving average of $3.72.

Insider Activity at Adagene

In other news, CEO Peter Luo bought 22,966 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were purchased at an average cost of $3.65 per share, with a total value of $83,825.90. Following the acquisition, the chief executive officer directly owned 67,966 shares in the company, valued at $248,075.90. This represents a 51.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 25,245 shares of company stock valued at $92,344 in the last quarter. 21.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Adagene

A hedge fund recently raised its stake in Adagene stock. Fifth Lane Capital LP lifted its position in Adagene Inc. Sponsored ADR (NASDAQ:ADAG – Free Report) by 427.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 145,000 shares of the company’s stock after buying an additional 117,500 shares during the quarter. Fifth Lane Capital LP owned about 0.31% of Adagene worth $274,000 as of its most recent filing with the SEC. Institutional investors own 9.51% of the company’s stock.

Key Stories Impacting Adagene

Here are the key news stories impacting Adagene this week:

Positive Sentiment: HC Wainwright reiterated a Buy rating and $7 price target. The target implies meaningful upside from recent trading levels and provides a positive signal for investor sentiment. Adagene Earns Buy Rating from HC Wainwright
Positive Sentiment: HC Wainwright raised its projected loss estimates for fiscal 2027 through fiscal 2030, forecasting losses of $0.42, $0.70, $1.07 and $0.87 per share, respectively, compared with previously wider losses. The revisions suggest improved expectations for Adagene’s longer-term financial performance. Adagene analyst estimates
Positive Sentiment: At the H.C. Wainwright conference, Adagene highlighted its high-dose CTLA-4 therapy, keeping investor attention focused on the company’s antibody-immunotherapy pipeline and potential clinical value. Adagene at H.C. Wainwright conference
Neutral Sentiment: Adagene also presented at Morgan Stanley’s Global Healthcare Conference, offering additional visibility for its development programs but no clearly disclosed near-term commercial catalyst. Adagene Morgan Stanley conference transcript
Negative Sentiment: HC Wainwright lowered its fiscal 2026 loss forecast to $0.43 per share from $0.37, indicating weaker near-term earnings expectations. Separately, another report cited a 10.44% reduction in a price target to $10.50, which could temper enthusiasm despite the bullish H.C. Wainwright view. Adagene price target reduced

About Adagene

(Get Free Report)

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene’s technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.